Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study

Affiliations

• ¹ Medical Oncology, Hacettepe University, Ankara, Turkey.
• ² Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India.
• ³ Medical Oncology, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
• ⁴ Medical Oncology, The First Affiliated Hospital of Sun Yat-sen, Guangzhou, Guangzhou, Guangdong Province, China.
• ⁵ Radiotherapy and Oncology, National Cancer Institute, Putrajaya, Malaysia.
• ⁶ Medical Oncology, Dr. Tarek Hashem's Clinic, Cairo, Egypt.
• ⁷ Clinical Oncology, Sultan Ismail Hospital, Johor Bahru, Malaysia.
• ⁸ Medical Oncology, Ege University, Izmir, Turkey.
• ⁹ Department of Urology, Taipei Veterans General Hospital and Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
• ¹⁰ Oncology, Novartis Healthcare Pvt. Ltd., Hyderabad, Telangana, India.
• ¹¹ Oncology, Novartis Pharma AG, Basel, Switzerland.
• ¹² Oncology, Novartis Pharma SAS, Rueil-Malmaison, France.
• ¹³ Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. [email protected].